ACADIA Pharmaceuticals (NASDAQ: ACAD) has recently received a number of price target changes and ratings updates:
- 8/17/2026 – ACADIA Pharmaceuticals had its price target raised by UBS Group AG from $45.00 to $49.00. They now have a “buy” rating on the stock.
- 8/12/2026 – ACADIA Pharmaceuticals was upgraded by Weiss Ratings from “hold (c)” to “hold (c+)”.
- 8/12/2026 – ACADIA Pharmaceuticals had its price target raised by Needham & Company LLC from $38.00 to $41.00. They now have a “buy” rating on the stock.
- 8/10/2026 – ACADIA Pharmaceuticals was given a new $27.00 price target by Morgan Stanley.
- 8/10/2026 – ACADIA Pharmaceuticals had its price target raised by Citigroup Inc. from $35.00 to $39.00. They now have a “buy” rating on the stock.
- 8/8/2026 – ACADIA Pharmaceuticals was upgraded by Wall Street Zen from “hold” to “buy”.
- 8/6/2026 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright.
- 8/5/2026 – ACADIA Pharmaceuticals had its price target raised by Royal Bank Of Canada from $36.00 to $37.00. They now have an “outperform” rating on the stock.
- 8/5/2026 – ACADIA Pharmaceuticals had its price target raised by Oppenheimer Holdings, Inc. from $23.00 to $25.00. They now have a “market perform” rating on the stock.
- 8/5/2026 – ACADIA Pharmaceuticals had its “market outperform” rating reaffirmed by Citigroup Inc..
- 8/5/2026 – ACADIA Pharmaceuticals had its price target raised by Citizens Jmp from $35.00 to $36.00. They now have a “market outperform” rating on the stock.
- 7/29/2026 – ACADIA Pharmaceuticals had its “hold (c)” rating reaffirmed by Weiss Ratings.
- 7/29/2026 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by Bank of America Corporation. They now have a $14.50 price target on the stock.
- 7/21/2026 – ACADIA Pharmaceuticals had its price target raised by BMO Capital Markets from $34.00 to $36.00. They now have an “outperform” rating on the stock.
- 7/21/2026 – ACADIA Pharmaceuticals had its price target raised by Stifel Nicolaus from $24.00 to $25.00. They now have a “hold” rating on the stock.
- 7/7/2026 – ACADIA Pharmaceuticals had its price target raised by Royal Bank Of Canada from $29.00 to $36.00. They now have an “outperform” rating on the stock.
- 6/30/2026 – ACADIA Pharmaceuticals was downgraded by HC Wainwright from “buy” to “hold”.
- 6/30/2026 – ACADIA Pharmaceuticals had its price target raised by Bank of America Corporation from $29.00 to $30.00. They now have a “buy” rating on the stock.
- 6/29/2026 – ACADIA Pharmaceuticals had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $37.00 price target on the stock.
- 6/29/2026 – ACADIA Pharmaceuticals had its price target raised by Citigroup Inc. from $32.00 to $35.00. They now have a “buy” rating on the stock.
- 6/29/2026 – ACADIA Pharmaceuticals had its price target raised by Canaccord Genuity Group Inc. from $32.00 to $36.00. They now have a “buy” rating on the stock.
Insider Buying and Selling at ACADIA Pharmaceuticals
In other ACADIA Pharmaceuticals news, EVP Elizabeth H.Z. Thompson sold 16,558 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $26.13, for a total transaction of $432,660.54. Following the completion of the transaction, the executive vice president directly owned 18,994 shares of the company’s stock, valued at approximately $496,313.22. This trade represents a 46.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider James Kihara sold 5,401 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $21.18, for a total transaction of $114,393.18. Following the transaction, the insider owned 24,509 shares of the company’s stock, valued at $519,100.62. This represents a 18.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 42,100 shares of company stock worth $1,134,287. 26.20% of the stock is currently owned by insiders.
The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.
See Also
- Five stocks we like better than ACADIA Pharmaceuticals
- 3 Energy Stocks Raising Dividends as the Sector Surges
- 5 Reasons the S&P 500 Could Keep Rallying Through Year-End
- Walmart’s Post-Earnings Drop Could Be a Buying Opportunity
- The Trade Desk’s Earnings Miss Raises a Bigger Question About Its AI Future
Receive News & Ratings for ACADIA Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.
